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Abstract The human gut contains trillions of commensal
bacteria, and similar to pathogenic bacteria, the gut microbes
and their products can be recognized by toll-like receptors
(TLRs). It is well acknowledged that the interaction between
gut microbiota and the local TLRs help to maintain the ho-
meostasis of intestinal immunity. High-fat intake or obesity
can weaken gut integrity leading to the penetration of gut
microbiota or their bacterial products into the circulation, lead-
ing to the activation of TLRs on immune cells and subsequent-
ly low-grade systemic inflammation in host. Metabolic cells
including hepatocytes and adipocytes also express TLRs.
Although they are able to produce and secrete inflammatory
molecules, the effectiveness remains low compared with the
immune cells embedded in the liver and adipose tissue. The
interaction of TLRs in these metabolic cells or organs with gut
microbiota remains unclear, but a few studies have suggested
that the functions of these TLRs are related to metabolism.
Alteration of the gut microbiota is associated with body
weight change and adiposity in human, and the interaction
between the commensal gut microbiota and TLRs may possi-
bly involve both metabolic and immunological regulation. In
this review, we will summarize the current findings on the
relationship between TLRs and gut microbiota with a focus
on metabolic regulation and discuss how such interaction par-
ticipates in host metabolism.
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Introduction
Trillions of commensal bacteria reside in our gastrointestinal
tract, and the interactions between gut microbiota and the toll-
like receptors (TLRs) on intestinal epithelial cells and immune
cells help to maintain the homeostasis of our immune system
[1]. TLRs are also expressed in hepatocytes and adipocytes.
Although they are able to produce inflammatory molecules,
the effectiveness remains low compared with the immune
cells embedded in the liver and adipose tissue, rendering the
function of TLRs in these cells elusive [2–4]. A few studies
suggest that their function is metabolism-related [5]. Several
global knockout models of TLRs or related pathways includ-
ing TLR2, TLR5, interferon regulatory factor-3 (IRF3), and
IRF5 which represent defects in immunity show an increase in
body weight or fat mass regardless of other metabolic pheno-
types [6–9]. The cell-specific knockout models also show the
metabolic link, but the phenotypes are rather diverse. For ex-
ample, hepatocyte-specific TLR4-knockout model shows an
improvement in overall metabolic phenotypes upon high-fat
diet challenge, but conversely, the same specific TLR5-
knockout model displays an opposite phenotype including
increased body weight, fatty liver, and fasting blood glucose
[10, 11]. Inflammation mediated by TLR activation leads to
downregulation of metabolism-related genes in the adipose
tissue and liver [12]. Low-grade inflammation is often ob-
served in obesity and metabolic diseases due to the increased
gut permeability, and presumably, the penetration of
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molecules produced by gut microbiota can activate peripheral
TLRs [13]. One of the functions of TLR pathway is to regulate
intrinsic metabolism in immune cells in order to spare the
energy for immune response [14]. Whether such energy relo-
cation happens at an intercellular level or even cross-organ
level remains unknown. The function of TLRs in innate and
adaptive immunity and how TLRs modulate host immunity
via the interaction with gut microbiota are reviewed elsewhere
[15]. In this review, wemainly focus on the current findings of
the relationship between TLRs and gut microbiota in terms of
metabolic regulation and discuss how such interaction sup-
ports the hypothesis of intercellular energy relocation in the
host, and its clinical implication in obesity and metabolic
diseases.
Metabolic regulation by TLR pathway at cellular
level
Glucose metabolism It is well known that glycolysis plays a
crucial role in macrophage polarization and dendritic cell ac-
tivation. In the resting state, dendritic cells utilize lipid as their
energy source through β-oxidation and oxidative phosphory-
lation [14, 16]. Engagement of TLR with its ligand activates
the PI3K/Akt pathway and leads to a metabolic switch
towards glycolysis to generate ATP [17]. Activation of the
downstream kinases TBK1 and IKKε upon TLR binding in-
duces phosphorylation of Akt, and activation of Akt triggers
the enrichment of the rate-limiting enzyme for glycolysis,
hexokinase-II, in the mitochondrial fraction and increases its
activity [18]. During M1 macrophage polarization, a isoform
switch of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFK2) from liver type (L-PFK2) to a more
active ubiquitous type (u-PFK2) is observed, causing a higher
glycolytic flux, and the switch is dependent on TLR (TLR2, 3,
4, and 9) pathway [19]. Conversely, duringM2 polarization of
macrophage in helminth infection, TLR2- and TLR4-
dependent activation of MAPK cascade, and subsequently,
CREB leads to IL-10 production and concurrent alteration of
a series of metabolism-related genes including aconitase and
ADP-dependent glucokinase [20]. Instead of aerobic glycoly-
sis, the M2 macrophages rely on oxidative phosphorylation to
utilize glucose as their energy source [20] (Fig. 1).
Lipid metabolismActivation of TLR3 and TLR4 in viral and
bacterial infection suppresses the expression of liver X recep-
tor (LXR)-dependent genes that regulate cholesterol efflux in
macrophages [21]. The retained cholesterol acts as a reserve
for the phagocytic process of macrophages [22], though in the
case of atherosclerosis, it promotes foam cell formation [21,
Drosophila
Immune cell
Fig. 1 Intracellular energy relocation in fat body cell of Drosophila and
immune cell of human. The fat body cell of Drosophila function as both
metabolic and immune cell. Activation of toll and its adaptors, tube and
dMyD88, results in the recruitment of Pelle kinase, subsequently
inactivation of cactus (an orthologue of IκB), and the release of Dif (a
transcription factor for antimicrobial genes). Simultaneously, insulin
signaling is antagonized by the related proteins regulated by
toll-induced Dif activation (left panel). Upon infection, activation of
TLR in immune cell such as macrophage or dendritic cell stimulates
inflammatory responses via the NFκB or IRF3 pathway, and IRF3 can
also regulatemetabolic response through interfering with the transcription
activity of LXR, FXR, and RXR. In addition, phosphorylation of Akt
mediated by the downstream kinases of TLR results in induction of
glycolysis to generate ATP. Energy is being utilized to sustain the
antimicrobial response (right panel)
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23]. The activation of IRF3, a key downstream nuclear factor
of TLR3 signaling, in response to viral infection on the one
hand stimulates antiviral response through the production of
interferons, and on the other hand suppresses metabolic re-
sponse by downregulating retinoid X receptor-α (RXRα)
[24]. RXRα can form heterodimers with other nuclear factors
including peroxisome proliferator-activated receptor-γ
(PPARγ), LXR, and farnesoid X receptor (FXR) which to-
gether construct a nuclear network regulating metabolism-
related genes [25]. Such suppression is key to prevent viral
assembly, as viruses can utilize host’s lipids to facilitate their
own replication [26]. Injection of TLR3, TLR4, TLR5, TLR7,
or TLR9 ligand in hepatitis B virus transgenic mice is shown
to inhibit viral replication [27].
However, unlike acute response that inhibits storage and
increases energy expenditure, chronic activation of TLR4 by
subinfectious dose of LPS in macrophages facilitates fatty
acid uptake and storage in the form of triglycerides with a
parallel decrease in lipolysis and β-oxidation [28, 29]. The
stimulated uptake and storage of triglycerides are also ob-
served in adipose tissue macrophages during obesity, and the
lipid accumulation is related to liposomal biogenesis [30]. The
reason for a switch from glycolysis to lipid storage when low-
grade inflammation sustains, and whether it is a physiological
or pathophysiological phenotype is, however, unclear. It pos-
sibly serves as an adaptive mechanism to acquire an external
source of energy to sustain inflammatory or antimicrobial re-
sponses, and prevent bacteria from utilizing pyruvate and
acetyl-CoA for their growth, thereby limiting their growth.
Theory of energy relocation: from immunity
to obesity
Fighting against infection requires high turnover of energy
[18, 31]. It is hypothesized that organisms are able to free
the energy from anabolism to immunological utilization upon
infection. Such energy relocation has been reported in lower
rank organisms; whereas in higher rank animals and human,
the findings limit to the intrinsic behaviors within immune
cells (Fig. 1) [32, 33]. The Btoll^ in TLR was originally de-
rived from such protein found inDrosophila. The functions of
TLR-related molecules in these lower organisms do not limit
to immunity but also include embryonic development [34].
Toll locates at the fat body cells in Drosophila and facilitates
biosynthetic and metabolic activities [34]. The fat body is
analogous to the liver and adipose tissue in human [32].
However, the fat body cells not only store excess nutrient
but also synthesize hemolymph proteins, circulating metabo-
lites as well as antimicrobial peptides [32]. In Drosophila,
activation of toll through genetic and fungal stimulation sup-
presses insulin signaling pathway resulting in decreased nutri-
ent storage and growth, and sparing of energy for the induced
immunity [33]. The fat body cell is a single compartment with
multiple functions, and such intrinsic metabolic regulation by
toll allows an internal shift of energy utilization from usual
growth and storage to immunological activities.
As the complexity of biostructure increases along the evo-
lution of higher rank organisms, the metabolic and immune
cells/organs are separated in origin. The metabolic functions
of TLR pathway have been observed in immune cells only,
and such regulations remain to be immunity-related in higher
animals and human (see previous section). Nonetheless, TLRs
are expressed in non-immune cells including adipocytes, he-
patocytes, and smooth muscle cells. Although the majority of
studies reported that their functions are to produce inflamma-
tory molecules, such kind of duplicate functions seems to be
redundant owing to the embedded immune cells in these tis-
sues. In fact, a few studies have shown the metabolic functions
of TLR pathway in the metabolic organs and cells. For exam-
ple, activation of TLR4 by lipopolysaccharides (LPS) sup-
presses the expression of phosphoenolpyruvate carboxykinase
(PEPCK) in the liver and adipose tissue, and the authors sug-
gest that such decrease would result in downregulated gluco-
neogenesis in the liver and lipogenesis in adipose tissue [12].
TLR4 pathway is also shown to inhibit lipogenesis in muscle
during fasting, and TLR4-deficient mice display a significant-
ly higher fat mass in fasted state compared with the wild type
control [35]. Moreover, treatment with LPS in rat stimulates
lipolysis in adipocytes in a TLR4-dependent manner [5]
(Fig. 1). These findings are consistent with the outcome of
intrinsic metabolic regulation by the TLR pathway that energy
is released for immunological activities rather than being
stored. However, a slight decrease in body weight and adipos-
ity with improved inflammatory status is observed in TLR4-
deficient mice fed a high saturated or monosaturated fat diet,
which is against the molecular mechanism of TLR4-inhibited
storage of energy [36]. It is important to note that inflamma-
tion induced by immune cells in obesity aggravates insulin
resistance and metabolic defects. Such dilemma is possibly
because the amelioration due to suppressed inflammatory re-
sponse in immune cells outweighs the sequels of the absence
of TLR-mediated catabolic events in metabolic cells during
long-term overnutrition in the TLR4-knockout model. By
contrast, another member, TLR5, is known to play a key role
in regulating colonization of gut microbiota, and its knockout
model shows a drastic increase in fat mass under both normal
and high-fat diet compared with wild type [1, 7]. Unlike the
TLR4-deficient model, TLR5-knockout mice show a higher
serum IL-1β level (i.e., pro-inflammatory status) under high-
fat diet compared with wild type, which indicates an absence
of immunosuppressive effect. Therefore, the inhibition of ca-
tabolism observed in these TLR5-deficient mice dominates.
In other words, the systemic metabolic phenotypes ob-
served in these TLR-knockout models would depend on the
balance between the degree of altered inflammation and the
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direct metabolic functions of TLRs. This balance varies
among different TLRs possibly because (1) the expressions
of TLRs vary in the intestine, and their blockade would thus
yield the penetration of different types and amount of gut
microbial products [15]. (2) The types of immunological func-
tion can be affected by the subcellular location of TLRs. For
example, endosomal TLRs such as TLR3, TLR7, and TLR9
and internalization of membrane TLR4 and TLR2 into endo-
some result in production of type I interferons which are usu-
ally considered as anti-inflammatory mediators [37, 38]. The
production of anti-inflammatory mediators along with the dis-
tinct metabolic functions of TLRs may affect the overall met-
abolic phenotypes. (3) The TLR-mediated metabolic func-
tions differ in degree in the liver, adipose tissue, or muscle
due to the diversity in cell types and TLR expression in these
organs, and ectopic accumulation of lipids or energy away
from the normal storage sites possibly aggravates metabolic
dysfunction. In order to make the concept of TLR agonism/
antagonism pharmacologically applicable, it is important to
comprehensively investigate the expressions of TLRs in dif-
ferent non-immune cells and organs. For example, under-
standing the roles of intestinal TLRs in blocking the penetra-
tion of bacterial products would allow us to predict the avail-
ability of TLR ligands to tissues in disease states. The evalu-
ation of metabolic and immunological capacities of TLRs in
different metabolic cells using cell-specific knockout models
along with in vitro studies would give us insight on generation
of specific TLR agonists or antagonists for different diseases
[2, 39].
Interaction between gut microbiota and TLRs:
possible intercellular energy relocation
The commensal microbes reside throughout our bodies
including the skin, oral cavity, and gut, and the human
gut contains 1014 bacteria which outnumber the total
number of cells in all physiological compartments.
Several TLRs have been found to affect the colonization
of gut microbiota [1, 6]. For example, the first contact of
gut microbiota with the intestinal lining triggers the acti-
vation of TLR5 in epithelial cells and dendritic cells,
resulting in the recruitment of B cells and T cells, and
subsequently the production of IgA to limit the
overcolonization of gut microbiota [40]. TLR2 on T cells
can sense the polysaccharide A on Bacteroides fragilis
and control its colonization [41]. Instead of triggering
major inflammation, TLRs in fact protect the host from
hyperinflammation by limiting the access of bacterial
products to cytosolic inflammasome, and by atypically
inhibiting NFκB activation in intestinal epithelium [42,
43]. However, a study argues that the alteration of gut
microbiota observed in TLR-deficient mice is due to the
familial transmission attributed by housing environment
or maternal transmission rather than the defects in immu-
nity [44]. Nonetheless, regardless whether TLR has a role
in alteration of gut microbiota, from the perspective of
receptor-ligand dynamics, we are concerned about how
much and what type of TLR ligands penetrate and what
the final outcomes of TLR activation are. Certainly, we
cannot rule out the possibility that change in diet or alter-
ation of gut microbiota would also alter the expressions of
TLRs, thus affecting the location of TLR-mediated cata-
bolic events.
High-fat intake or obesity can weaken the gut integrity
leading to penetration of gut microbes or their products into
the circulation [45]. This low-grade endotoxemia triggered by
the commensal microbiota is believed to be the cause of TLR
activation. Body weight change and increased adiposity are
associated with alteration of gut microbiota, and the interac-
tion between gut microbiota and TLRs can be both immuno-
logical and metabolic. Although there is yet any direct evi-
dence showing metabolic regulation by gut microbiota-
induced TLR activation, several studies have demonstrated
that the metabolic functions of TLR pathway can be triggered
by low-dose LPS which is similar to the range found in
obesity-induced metabolic endotoxemia [5, 12]. If the concept
of intercellular energy relocation holds true, immune or in-
flammatory response would be stimulated during nutrient
overload while anabolic event would simultaneously be sup-
pressed, which creates an insulin resistance-like condition.
Changes in gut microbiota and intestinal permeability occur
rapidly after initiation and termination of high-fat diet [46].
Assuming that sensitivity of TLRs is different in immune cells
and metabolic cells, it is possible that the TLRs in the meta-
bolic cells are more sensitive to the gut microbiota-derived
endotoxemia, thereby metabolic alteration would be engaged
first. Such metabolic regulation facilitates intercellular or
inter-organ relocation of energy to prepare for the future pos-
sible full-blown attack of microbes. It would be problematic in
the situation of overnutrition when the energy is not stored in
the proper locations such as adipose tissue (Fig. 2). As exces-
sive intake of energy continues, other metabolic pathways are
activated. Expansion of adipose tissue results in high turnover
of adipocytes as well as lipid content, and for adaptation, both
catabolic and anabolic rates remain high. Excess energy con-
tinuously overflows to other organs. Our body may be misled
by the sustained metabolic endotoxemia that the infec-
tion has not been subsided, resulting in infiltration of
immune cells to the organs, and the immune cells in
turn store the energy to sustain the inflammatory re-
sponses [28–30] (Fig. 2). In fact, it is shown that in-
flammation does not contribute to metabolic dysfunction
in short-term high-fat diet, and the observed early-onset
insulin resistance is possibly caused by lipid overload in
the liver and muscle instead [47].
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Fig. 2 Hypothesis of intercellular energy relocation triggered by gut
microbiota. Dietary alteration can result in change of gut microbiota
and weakening of gut integrity, subsequently penetration of gut
microbes and their products. The TLRs on metabolic cell such as
adipocyte can sense the low amount of gut bacteria-derived TLR ligands,
which leads to catabolic events including lipolysis. Energy or nutrient is
shunted to other locations. Activation of the TLR pathway turns on
glycolysis in immune cell (e.g., macrophage) to initiate polarization
(upper panel). When the change in diet persists, e.g., overeating in
obesity, other metabolic mechanisms are activated. Expansion of adipose
tissue results in high turnover of lipids in adipocytes. Excess energy
continuously overflows to other organs. More immune cells infiltrate into
those organs, and energy or lipids are now taken up by the adjacent
macrophages for their own utilization to sustain inflammation, which
aggravates metabolic dysfunction (middle panel). The glycolysis and
lipolysis pathways are briefly depicted in the boxes at the bottom (bottom
panel)
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Clinical implication of interfering the crosstalk
between gut microbiota and TLRs
The concept of energy relocation between immunity and me-
tabolism is based on a nutrient- or energy-scarce environment
[33]. Nonetheless, the current issue faced by humankind is the
long-term medical problems due to overnutrition. Obesity is
often associated with metabolic endotoxemia which stimu-
lates local and systemic inflammation and eventually aggra-
vates metabolic dysfunction and cardiovascular risks. As a
result, anti-inflammation seems to be a therapeutic option for
obesity-associated diseases. However, the clinical benefit is
yet conclusive, and in the case of diabetes, use of anti-
inflammatory drug even increases the risk of cardiovascular
event. [48] In addition, in spite of the consistent beneficial
effects on metabolic functions shown in TLR-deficient animal
models, no conclusive association between TLR polymor-
phism and metabolic diseases can be drawn from existing
human data [49, 50]. A study reported that among 1894 pa-
tients without acute myocardial infarction but requiring coro-
nary angiography, the prevalence of diabetes was 7% lower in
those with the TLR4 polymorphism (Asp299Gly) variant al-
lele compared with the wild type allele [51]. In contrast, an-
other study selecting a subpopulation of 722 subjects in the
Cooperative Health Research in the Augsburg Region
(KORA) Survey 2000 found no association with type 2 dia-
betes, impaired glucose tolerance, or other components of
metabolic syndrome in the heterozygous and homozygous
TLR4 variant alleles [50]. On the other hand, a nonsense
TLR5 polymorphism prevents weight gain but imposes risk
for diabetes [52]. Two studies on the association of TLR2
polymorphism (rs3804100, 1350 T/C) with type 1 diabetes
showed conflicting results [53, 54]. These discrepancies may
be partially related to the geographic, socioeconomic, or epi-
genetic influence on gut microbiota of the individuals.
Likewise, even though it is well accepted that alteration of
gut microbiota can contribute to obesity and metabolic dys-
function, results from different laboratories appear to be in-
consistent. The evolutionary purpose of gut microbiota is re-
lated to enhanced energy harvesting in host [55], and deple-
tion of gut microbiota using antibiotics can promote browning
of white adipose tissue and thus prevent obesity [56].
However, antibiotics have been wildly used in agriculture to
stimulate weight gain of livestock in recent decades [57]. Use
of antibiotics in early stage of life is associated with childhood
obesity. Also, even within the same genus of Lactobacillus,
the strain Lactobacillus plantarum promotes weight loss
whereas Lactobacillus ingluiviei and Lactobacillus
acidophilus induce weight gain [58, 59]. It is no doubt
that the idea of manipulating gut microbiota to regulate
body weight and metabolism requires further detailed
investigation due to the complex relationship between
the host and gut microbiota.
Gut microbiota pattern can be shaped by diet and substan-
tial differences are observed in carnivores, omnivores, and
herbivores [60]. Low-grade systemic inflammation induced
by high-fat diet may be an evolutional protective mechanism
against food-borne pathogens particularly derived from
ingesting animal fat where cross infection is highly possible.
In modern medicine, antagonists of TLR for metabolic and
cardiovascular diseases have been explored because of the
beneficial effects yielded by immunosuppression. However,
if gut microbiota-derived molecules in these chronic diseases
can activate TLRs, catabolism in the host would be predicted.
Inhibition of the TLR pathway in such scenario would pro-
mote the energy storage; however, considering the variation in
types of penetrated bacterial products and expression of TLRs
in different organs and cell types, it might result in undesirable
anabolic events in certain location, which would exacerbate
the metabolic dysfunction. In addition, there are concerns of
suppressing host TLR activity because it increases the vulner-
ability to infection which is also a contemporary medical is-
sue. A thorough investigation on the functions of the TLR
pathway and the interaction between TLRs and gut microbiota
will allow us to better evaluate on the clinical application of
agonism/antagonism of TLRs in chronic diseases.
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